{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T03:01:03Z","timestamp":1786762863413,"version":"build-2736575974"},"reference-count":25,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Introda significant: Onychomycosis is the most common nail disorder seen in clinical practice, and it may have significant impact on patient quality of life. Understanding risk factors for onychomycosis may help to devise screening and treatment guidelines for populations that are more susceptible to this infection. Using a national database, we aimed to explore associations between onychomycosis and age, sex, and underlying medical conditions, as well as to examine current onychomycosis treatment trends. Materials and Methods: We performed a nested, matched, case\u2013control study of patients in the All of Us database aged \u2265 18 years (6 May 2018\u20131 January 2022). Onychomycosis cases were identified using International Classification of Diseases (ICD) and Systematized Nomenclature of Medicine (SNOMED) diagnostic codes (ICD-9 110.1, ICD-10 B35.1, SNOMED 414941008). Demographic information (i.e., age, sex, and race), treatments, and co-diagnoses for onychomycosis patients and case\u2013controls were recorded. Wald\u2019s test applied to multivariate logistic regression was used to calculate odds ratios and p-values between onychomycosis and co-diagnoses. Additionally, 95% confidence intervals were calculated with a proportion test. Results: We included 15,760 onychomycosis patients and 47,280 matched controls. The mean age of onychomycosis patients was 64.9 years, with 54.2% female, 52.8% Non-Hispanic White, 23.0% Black, 17.8% Hispanic, and 6.3% other, which was similar to controls. Patients with onychomycosis vs. controls were more likely to have a co-diagnosis of obesity (46.4%, OR 2.59 [2.49\u20132.69]), tinea pedis (21.5%, OR 10.9 [10.1\u201311.6]), peripheral vascular disease (PVD) (14.4%, OR 3.04 [2.86\u20133.24]), venous insufficiency (13.4%, OR 3.38 [3.15\u20133.59]), venous varices (5.6%, OR 2.71 [2.47\u20132.97]), diabetes mellitus (5.6%, OR 3.28 [2.98\u20133.61]), and human immunodeficiency virus (HIV) (3.5%, OR 1.8 [1.61\u20132.00]) (p &lt; 0.05, all). The most frequently prescribed oral and topical medications were terbinafine (20.9%) and ciclopirox (12.4%), respectively. The most common therapeutic procedure performed was debridement (19.3%). Over the study period, ciclopirox prescriptions (Spearman correlation 0.182, p = 0.0361) and fluconazole prescriptions increased (Spearman correlation 0.665, p = 2.44 \u00d7 10\u22124), and griseofulvin (Spearman correlation \u22120.557, p = 0.0131) and itraconazole prescriptions decreased (Spearman correlation \u22120.681, p = 3.32 \u00d7 10\u22126). Conclusions: Our study demonstrated that age, obesity, tinea pedis, PVD, venous insufficiency, diabetes mellitus, and HIV were significant risk factors for onychomycosis. In addition, the most frequent oral and topical onychomycosis medications prescribed were terbinafine and ciclopirox, likely reflective of efficacy and cost considerations. Identifying and managing these risk factors is essential to preventing onychomycosis\u2019 primary infections and recurrences and improving treatment efficacy.<\/jats:p>","DOI":"10.3390\/jof9070712","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T01:14:12Z","timestamp":1688087652000},"page":"712","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Risk Factors and Treatment Trends for Onychomycosis: A Case\u2013Control Study of Onychomycosis Patients in the All of Us Research Program"],"prefix":"10.3390","volume":"9","author":[{"given":"Samantha Jo","family":"Albucker","sequence":"first","affiliation":[{"name":"Tulane University School of Medicine, New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5068-6803","authenticated-orcid":false,"given":"Julianne M.","family":"Falotico","sequence":"additional","affiliation":[{"name":"Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Ning","family":"Choo","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY 10021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T.","family":"Matushansky","sequence":"additional","affiliation":[{"name":"Columbia University, New York, NY 10027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-9304","authenticated-orcid":false,"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Weill Cornell Medicine, New York, NY 10021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaad.2018.03.062","article-title":"Onychomycosis: Clinical Overview and Diagnosis","volume":"80","author":"Lipner","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000485632","article-title":"The Impact of Onychomycosis on Quality of Life: A Systematic Review of the Available Literature","volume":"4","author":"Gupta","year":"2018","journal-title":"Skin Appendage Disord."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jaad.2020.05.143","article-title":"Effect of onychomycosis and treatment on patient-reported quality-of-life outcomes: A systematic review","volume":"85","author":"Stewart","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00403-022-02413-4","article-title":"Onychomycosis in underrepresented groups: An all of us database analysis","volume":"315","author":"Moseley","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1468-3083.2000.00124.x","article-title":"The epidemiology of onychomycosis: Possible role of smoking and peripheral arterial disease","volume":"14","author":"Gupta","year":"2000","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2340\/00015555-1576","article-title":"Onychomycosis as a warning sign for peripheral arterial disease","volume":"93","author":"Fukunaga","year":"2013","journal-title":"Acta Derm. Venereol."},{"key":"ref_7","first-page":"38","article-title":"Risk Factors and Comorbidities for Onychomycosis","volume":"8","author":"Elewski","year":"2015","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_8","first-page":"146","article-title":"Evaluation of obesity-associated dermatoses in obese and overweight individuals","volume":"45","author":"Doner","year":"2011","journal-title":"Turkderm"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/archderm.142.10.1279","article-title":"Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: A survey of 2761 patients","volume":"142","author":"Szepietowski","year":"2006","journal-title":"Arch. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Markinson, B.C., and Caldwell, B.D. (J. Am. Podiatr. Med. Assoc., 2015). Efinaconazole Topical Solution, 10%: Efficacy in Patients with Onychomycosis and Coexisting Tinea Pedis, J. Am. Podiatr. Med. Assoc., ahead of print.","DOI":"10.7547\/14-088.1"},{"key":"ref_11","first-page":"492","article-title":"Management of onychomycosis and co-existing tinea pedis","volume":"14","author":"Lipner","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/1346-8138.12020","article-title":"Frequency of peripheral arterial disease and venous insufficiency in toenail onychomycosis","volume":"40","author":"Ozkan","year":"2013","journal-title":"J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.7863\/jum.2005.24.8.1085","article-title":"Venous insufficiency in patients with toenail onychomycosis","volume":"24","author":"Kulac","year":"2005","journal-title":"J. Ultrasound Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2133.1998.02464.x","article-title":"Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: A multicentre survey","volume":"139","author":"Gupta","year":"1998","journal-title":"Br. J. Dermatol."},{"key":"ref_15","first-page":"603","article-title":"Skin and nail mycoses in patients with diabetic foot","volume":"148","author":"Papini","year":"2013","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1046\/j.1365-4362.2000.00012.x","article-title":"Epidemiology and prevalence of onychomycosis in HIV-positive individuals","volume":"39","author":"Gupta","year":"2000","journal-title":"Int. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/archderm.134.10.1216","article-title":"Nail Changes in Patients Infected with Human Immunodeficiency Virus: A Prospective Controlled Study","volume":"134","author":"Cribier","year":"1998","journal-title":"Arch. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2021.10.007","article-title":"Analysis of utilization, cost and, prescription trends of onychomycosis medications among Medicare patients","volume":"86","author":"Wang","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jaad.2018.05.1260","article-title":"Onychomycosis: Treatment and prevention of recurrence","volume":"80","author":"Lipner","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jaad.2022.06.006","article-title":"Increased fluconazole usage by dermatologists in the Medicare provider utilization and payment database, 2014\u20132019","volume":"88","author":"Falotico","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/0190-9622(95)91454-4","article-title":"Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis","volume":"32","author":"Faergemann","year":"1995","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","unstructured":"GoodRx (2023, March 29). Ciclopirox. Available online: https:\/\/www.goodrx.com\/ciclopirox?utm_campaign=115230181&utm_content=115483975577&utm_source=google&utm_medium=cpc&utm_term=kwd-1172978949574&gclid=Cj0KCQjww4-hBhCtARIsAC9gR3b20nlsHMBP80S93EEJQGhP7q4p7Rf3s3-SkNJBRRFeVcq-17MmZQsaAp4YEALw_wcB&gclsrc=aw.ds."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7547\/21-221","article-title":"Poor Antifungal Coverage for Onychomycosis in a Cross-Sectional Analysis of Medicaid Formularies","volume":"112","author":"Falotico","year":"2022","journal-title":"J. Am. Podiatr. Med. Assoc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/14740338.2020.1829592","article-title":"Safety of current therapies for onychomycosis","volume":"19","author":"Ricardo","year":"2020","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00403-020-02044-7","article-title":"Retrospective analysis of adverse events with topical onychomycosis medications reported to the United States Food and Drug Administration","volume":"312","author":"Wang","year":"2020","journal-title":"Arch. Dermatol. Res."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/9\/7\/712\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:03:23Z","timestamp":1760126603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/9\/7\/712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["jof9070712"],"URL":"https:\/\/doi.org\/10.3390\/jof9070712","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}